Abstract: Techniques for training and using machine learning models for resource-level classification. A method for training includes refining outputs of a language model by providing a prompt and a set of sample resources to the language model over a series of iterations. Accuracies for the classifications output by the language model at each iteration are determined based on semantic similarity between those classifications and corresponding reference classifications for the sample resources. The language model is applied to data of a set of training resources when the outputs of the language model have been refined, in order to output a set of classifications for the set of training resources. Training data is labeled based on the set of classifications output by the language model. A classifier machine learning model is trained via supervised machine learning using the set of labeled training data in order to produce a trained classifier machine learning model.

Abstract: A method is provided for treating a cancer patient non-responsive to treatment with a cancer therapy by treating the patient with said cancer therapy in combination with an agent that blocks the activity of a dominant factor selected among the plurality of host-driven resistance factors generated in response to treatment of the cancer patient with the cancer therapy, these factors having a fold-change predictive of a non-favorable response of the cancer patient to the treatment with the cancer therapy.

Abstract: A method is provided for treating a cancer patient non-responsive to treatment with a cancer therapy by treating the patient with said cancer therapy in combination with an agent that blocks the activity of a dominant factor selected among the plurality of host-driven resistance factors generated in response to treatment of the cancer patient with the cancer therapy, these factors having a fold-change predictive of a non-favorable response of the cancer patient to the treatment with the cancer therapy.

Abstract: A method is provided for treating a cancer patient non-responsive to treatment with a immune checkpoint inhibitor (ICI) by treating the patient with said ICI in combination with an agent that blocks the activity of a dominant factor selected among the plurality of host-driven resistance factors generated in response to treatment of the cancer patient with the ICI, these factors having a fold-change predictive of a non-favorable response of the cancer patient to the treatment with the ICI.

Abstract: A method and a kit are provided for predicting a favorable or a non-favorable response of a cancer patient to treatment with an immune checkpoint inhibitor by determining in a biological sample obtained from the cancer patient, before and after the treatment, the changes of the levels of factors/biomarkers generated by the cancer patient in response to said treatment, and a method for treatment of a cancer patient with an immune checkpoint inhibitor.

Abstract: Provided are blocking agents to IL-1?, IL-1?, or IL-1R activity for use in combination with radiotherapy for treating cancer patients in which radiotherapy treatment induces IL-1?, IL-1? or both in their circulation.

Abstract: Methods of determining suitability to be treated with an immunotherapy comprising receiving a sample from the subject and determining the presence of Ly6E expressing neutrophils in the sample, wherein the presence of the Ly6E neutrophils indicates the subject is suitable for treatment are provided. Pharmaceutical composition comprising Ly6E neutrophils, and methods of treatment by administering Ly6E neutrophils are also provided.

Abstract: Methods of treating, ameliorating or preventing an acute respiratory disease or condition or cytokine storm in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising an effective amount of MSCs contacted with chemotherapy or conditioned media from the MSCs contacted with chemotherapy are provided.

Abstract: A method is provided for treating a cancer patient non-responsive to treatment with a immune checkpoint inhibitor (ICI) by treating the patient with said ICI in combination with an agent that blocks the activity of a dominant factor selected among the plurality of host-driven resistance factors generated in response to treatment of the cancer patient with the ICI, these factors having a fold-change predictive of a non-favorable response of the cancer patient to the treatment with the ICI.

Abstract: Provided are blocking agents to IL-1?, IL-1?, or IL-1R activity for use in combination with radiotherapy for treating cancer patients in which radiotherapy treatment induces IL-1?, IL-1? or both in their circulation.

Abstract: The invention relates to an activating composition comprising a cell, which may be any cell type used for cell therapy, wherein the cell is activated by a chemotherapy agent. Further, there is provided an activating composition comprising a supernatant of a composition comprising a cell, which may be any cell type used for cell therapy, wherein the cell is activated by a chemotherapy agent and wherein the supernatant is used as a therapy. The invention further provides methods for treating or preventing a disease or a condition comprising the use of the activated composition.

Abstract: Provided are blocking agents to IL-1?, IL-1?, or IL-1R activity for use in combination with radiotherapy for treating cancer patients in which radiotherapy treatment induces IL-1?, IL-1? or both in their circulation.

Abstract: A method is provided for treating a cancer patient non-responsive to treatment with a immune checkpoint inhibitor (ICI) by treating the patient with said ICI in combination with an agent that blocks the activity of a dominant factor selected among the plurality of host-driven resistance factors generated in response to treatment of the cancer patient with the ICI, these factors having a fold-change predictive of a non-favorable response of the cancer patient to the treatment with the ICI.

Abstract: A method for treating cancer and/or preventing or reducing metastasis or treating angiogenesis related disorders comprising the step of administering IL-31 or peptide which is at least about 70%, homologous to the IL-31 sequence as set forth in SEQ ID No. 1.

Abstract: A method is provided for treating a cancer patient non-responsive to treatment with a cancer therapy by treating the patient with said cancer therapy in combination with an agent that blocks the activity of a dominant factor selected among the plurality of host-driven resistance factors generated in response to treatment of the cancer patient with the cancer therapy, these factors having a fold-change predictive of a non-favorable response of the cancer patient to the treatment with the cancer therapy.

Abstract: Provided are blocking agents to IL-1?, IL-1?, or IL-1R activity for use in combination with radiotherapy for treating cancer patients in which radiotherapy treatment induces IL-1?, IL-1? or both in their circulation.

Abstract: A method and a kit are provided for predicting a favorable or a non-favorable response of a cancer patient to treatment with a cancer therapy by determining in a biological sample obtained from the cancer patient, before and after the treatment, the changes of the levels of factors/biomarkers generated by the cancer patient in response to said treatment, and a method for treatment of a cancer patient.

Abstract: A method and a kit are provided for predicting a favorable or a non-favorable response of a cancer patient to treatment with an immune checkpoint inhibitor by determining in a biological sample obtained from the cancer patient, before and after the treatment, the changes of the levels of factors/biomarkers generated by the cancer patient in response to said treatment, and a method for treatment of a cancer patient with an immune checkpoint inhibitor.

Abstract: A method for treating cancer and/or preventing or reducing metastasis or treating angiogenesis related disorders comprising the step of administering IL-31 or peptide which is at least about 70%, homologous to the IL-31 sequence as set forth in SEQ ID No. 1.

Abstract: A method for treating cancer and/or preventing or reducing metastasis or treating angiogenesis related disorders comprising as the step of administering IL-31 or peptide which is at least about 70%, homologous to the IL-31 sequence as set forth in SEQ ID No. 1.